Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically ...

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with s ...

A guide to the six best scar creams that work with modern beauty technology, from ultrasonic infusion devices and LED face wands to smart home sensors and AI-powered skin tracking apps.

Summary: Researchers compiled emerging evidence to prove that astrocytes, traditionally dismissed as passive, structural ...

BMIP, launched by government, will function complimentary to international insurers as its global recognition requires time ...

Jose Paul is a veteran port administrator with over three decades of experience in India’s maritime sector. Born in Njarackal in Ernakulam district, he began hi ...

ARVO presenters conducted a retrospective study to assess the visual and anatomical outcomes of patients receiving complement inhibitors for geographic atrophy. In a real-world cohort of patients with ...

(Getty) Recent developments in complement biology and targeted therapies represent important advancements in addressing some of the unresolved challenges in AAV. Despite major therapeutic advances, ...

C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...

ABSTRACT: As a completion of the previously published theory of higher-order types of asymptotic variation, we point out some remarks about different approaches to construct such an advanced and ...

It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...